Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in De Novo Kidney Allograft Recipients
NCT00556257Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Aug 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of tofacitinib in kidney transplant rejection (2 arms), sponsored by Pfizer. Primary endpoint: Clinical biopsy proven acute rejection rate at 6 months. Planned start Aug 2007; status: withdrawn.
02
Drugs
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00556257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00556257.